This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Biontech Rna Pharmaceuticals Gmbh. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Angelika Fruhwirth: Innovator in RNA Vaccine Development
Introduction
Angelika Fruhwirth is a prominent inventor based in Innsbruck, Austria. She has made significant contributions to the field of biotechnology, particularly in the development of RNA vaccines. Her innovative work has the potential to transform the landscape of allergy treatment and immunization.
Latest Patents
Angelika Fruhwirth holds a patent for an RNA vaccine that contains a RNA molecule encoding an allergen or its derivative. This groundbreaking invention aims to address allergies by utilizing the body's immune response to the specific allergen.
Career Highlights
Fruhwirth is associated with BioNTech RNA Pharmaceuticals GmbH, a leading company in the field of RNA-based therapeutics. Her work at BioNTech has positioned her as a key player in the advancement of RNA technology and its applications in medicine.
Collaborations
She collaborates with esteemed colleagues such as Elisabeth Rosler and Josef Thalhamer, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Angelika Fruhwirth's contributions to RNA vaccine development highlight her role as a pioneering inventor in biotechnology. Her work not only addresses critical health challenges but also paves the way for future advancements in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile